Sign up to read this article for FREE!
After signing up, you'll start to receive regular news updates from us.
HTG Introduces new Product to Measure MicroRNA
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
HTG, Inc., provider of the quantitative Nuclease Protection Assay (qNPA™) system and service partner for the life sciences industry, has announced the availability of a customizable qNPA™ ArrayPlate to measure microRNA or other small RNA molecules.
The customizable platform simplifies the workflow of gene expression analysis. It does not require the process of RNA extraction for measurement. qNPA measures the changes in gene expression due to the functional biology not as a consequence of the RNA extraction technique. Currently, most identified miRNAs can be measured with the qNPA ArrayPlate technology for human, rat, and mouse.
“HTG devised this functionality at the request of customers who have long sought a miRNA analysis solution that was quick, accurate, sensitive and reliable,” said TJ Johnson, president and CEO, HTG. “As such, HTG remains committed to enabling pharmaceutical and academic researchers to effectively screen drug compounds across hundreds to thousands of samples to help identify and move the most promising drug compounds through the research process.”
The new customizable qNPA ArrayPlate offering also allows researchers to measure miRNA and mRNA simultaneously in the same sample well.
The product is based on HTG’s qNPA ArrayPlate technology platform, which allows researchers to investigate a customized set of genes with precision.
HTG’s qNPA technology is used to carry out quantitative, multiplexed gene-based drug discovery programs, including target validation, HTS lead optimization, metabolism, toxicology and clinical development.
HTG’s platform is designed for high throughput automation; it allows scientists to test any sample, including fixed tissues, without RNA extraction or target amplification.
The customizable platform simplifies the workflow of gene expression analysis. It does not require the process of RNA extraction for measurement. qNPA measures the changes in gene expression due to the functional biology not as a consequence of the RNA extraction technique. Currently, most identified miRNAs can be measured with the qNPA ArrayPlate technology for human, rat, and mouse.
“HTG devised this functionality at the request of customers who have long sought a miRNA analysis solution that was quick, accurate, sensitive and reliable,” said TJ Johnson, president and CEO, HTG. “As such, HTG remains committed to enabling pharmaceutical and academic researchers to effectively screen drug compounds across hundreds to thousands of samples to help identify and move the most promising drug compounds through the research process.”
The new customizable qNPA ArrayPlate offering also allows researchers to measure miRNA and mRNA simultaneously in the same sample well.
The product is based on HTG’s qNPA ArrayPlate technology platform, which allows researchers to investigate a customized set of genes with precision.
HTG’s qNPA technology is used to carry out quantitative, multiplexed gene-based drug discovery programs, including target validation, HTS lead optimization, metabolism, toxicology and clinical development.
HTG’s platform is designed for high throughput automation; it allows scientists to test any sample, including fixed tissues, without RNA extraction or target amplification.
